Professor Latchman has a lengthy track record as a Fundraiser and Charity Supporter. For example he raised over £9 million whilst Dean of the Institute of Child Health at UCL. He has significant experience of the commercial exploitation of  intellectual property, having obtained Venture Capital Funding to found a Company (BioVex Ltd) on the basis of patents developed by his laboratory in the area of viral gene therapy. The Company was subsequently acquired by Amgen Ltd and its viral vector is now used in an approved treatment for patients with melanoma. He is also Non-Executive Chairman of Therakind Ltd, a Company which develops medicines for use in children.